Lung cancer causes ~160,000 deaths annually in the U.S. and prevention will be crucial to win the war on this deadliest cancer. Since DNA modification by tobacco carcinogens is one major driver for lung cancer initiation, blocking DNA adduct formation (the root cause) is a plausible strategy. This proposal focuses on the preclinical studies of dihydromethysticin (DHM) as a novel and highly efficacious chemopreventive agent that inhibits lung tumor initiation via preventing tobacco carcinogen-induced DNA modification. Preliminary data demonstrate that DHM (given during carcinogen exposure period at a dose of 50 ppm in diet) completely blocked NNK-induced lung tumor formation in A/J mice. A natural analog, dihydrokavain (DHK), was completely inactive even at 500 ppm in diet. Such a sharp in vivo difference suggests a crucial role of methylenedioxy functional group for specific targeting by DHM. DHM selectively reduced NNAL (the active metabolite of NNK)-induced DNA adducts in the lung tissues. DHM also reduced NNK-derived DNA adducts in F344 rats, indicating its cross-species anti-initiation potential. Based on the reported activity of DHM in activating aryl hydrocarbon receptor (AHR) and our own data of DHM in increasing glucuronidated NNAL in mouse urine, we propose that DHM activates detoxification pathways as the primary mechanism of action. With respect to safety, 17-week dietary exposure of DHM to A/J mice caused no adverse effects at 500 ppm, affording a wide safety margin as a lung cancer chemopreventive agent for long-term use. Our central hypothesis is that DHM effectively prevents tobacco carcinogen-induced lung tumorigenesis, at least in major part, by enhancing carcinogen detoxification potentially via activating AHR leading to a reduction in oncogenic DNA adducts in the target lung tissues. This hypothesis will be tested by accomplishing the following aims:
Aim 1 To elucidate the structural determinant(s) of DHM (i.e., intact DHM or its metabolite) for its exceptional in vivo inhibitory activities against NNK-induced DNA adduct formation and lung tumor initiation. Data will also inform the in vivo active form of DHM.
Aim 2 To investigate enhanced detoxification as a key mechanism of DHM to inhibit NNK-induced DNA adduct formation and lung tumor initiation. Data will also inform its potential to protect against other tobacco carcinogens and identify surrogate biomarkers for future translational studies.
Aim 3 To evaluate the efficacy of DHM against NNK-induced lung tumorigenesis in F344 rats and BaP-induced lung tumorigenesis in A/J mice. Data will inform its cross-species applicability and carcinogen specificity. If the results support our hypothesis, DHM will be well positioned for Good Laboratory Practice (GLP)-based toxicology in higher mammals in preparation for an IND application for human translation studies. The mechanistic knowledge will not only identify surrogate biomarkers critical for translation, but also advance our basic understanding about NNAL metabolism and carcinogenesis.

Public Health Relevance

Lung cancer is the No.1 cause of death among all malignancies. Chemoprevention is crucial to deal with this deadliest cancer at the root cause to substantially impact public health and clinical management. We developed this proposal based on solid preliminary data to focus on the preclinical studies in mice and rats of dihydromethysticin (DHM) as a novel, safe and highly efficacious chemopreventive agent that stops lung tumor initiation via blocking tobacco carcinogen-induced DNA modification. Data to be generated from this grant award will provide experimental evidence to support planning of clinical translation of this natural product to human lung cancer prevention.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA193278-05
Application #
9480715
Study Section
Chemo/Dietary Prevention Study Section (CDP)
Program Officer
Riscuta, Gabriela
Project Start
2016-09-01
Project End
2020-04-30
Budget Start
2018-05-01
Budget End
2019-04-30
Support Year
5
Fiscal Year
2018
Total Cost
Indirect Cost
Name
University of Florida
Department
Pharmacology
Type
Schools of Pharmacy
DUNS #
969663814
City
Gainesville
State
FL
Country
United States
Zip Code
32611
Wang, Yi; Eans, Shainnel O; Stacy, Heather M et al. (2018) A stable isotope dilution tandem mass spectrometry method of major kavalactones and its applications. PLoS One 13:e0197940
Zhuang, Chunlin; Zhang, Wen; Sheng, Chunquan et al. (2017) Chalcone: A Privileged Structure in Medicinal Chemistry. Chem Rev 117:7762-7810
Puppala, Manohar; Narayanapillai, Sreekanth C; Leitzman, Pablo et al. (2017) Pilot in Vivo Structure-Activity Relationship of Dihydromethysticin in Blocking 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone-Induced O6-Methylguanine and Lung Tumor in A/J Mice. J Med Chem 60:7935-7940
Zhuang, Chunlin; Wu, Zhongli; Xing, Chengguo et al. (2017) Small molecules inhibiting Keap1-Nrf2 protein-protein interactions: a novel approach to activate Nrf2 function. Medchemcomm 8:286-294
Tang, Su-Ni; Zhang, Jinhui; Jiang, Peixin et al. (2016) Gene expression signatures associated with suppression of TRAMP prostate carcinogenesis by a kavalactone-rich Kava fraction. Mol Carcinog 55:2291-2303
Narayanapillai, Sreekanth C; von Weymarn, Linda B; Carmella, Steven G et al. (2016) Dietary Dihydromethysticin Increases Glucuronidation of 4-(Methylnitrosamino)-1-(3-Pyridyl)-1-Butanol in A/J Mice, Potentially Enhancing Its Detoxification. Drug Metab Dispos 44:422-7
Narayanapillai, Sreekanth C; Lin, Shang-Hsuan; Leitzman, Pablo et al. (2016) Dihydromethysticin (DHM) Blocks Tobacco Carcinogen 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK)-Induced O6-Methylguanine in a Manner Independent of the Aryl Hydrocarbon Receptor (AhR) Pathway in C57BL/6 Female Mice. Chem Res Toxicol 29:1828-1834
Martin, Amanda C; Johnston, Ed; Xing, Chengguo et al. (2014) Measuring the chemical and cytotoxic variability of commercially available kava (Piper methysticum G. Forster). PLoS One 9:e111572
Narayanapillai, Sreekanth C; Balbo, Silvia; Leitzman, Pablo et al. (2014) Dihydromethysticin from kava blocks tobacco carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced lung tumorigenesis and differentially reduces DNA damage in A/J mice. Carcinogenesis 35:2365-72